Author: healthylife7

VCT220 is a novel nonpeptide, orally available glucagon-like peptide-1 receptor agonist (GLP-1RA) designed to reduce the complex administration of injectable GLP-1RAs and the limited bioavailability of on-marketing oral agents for obesity care. We conducted a multicenter, randomized, double-blind, placebo-controlled, phase II trial (Registration no. CTR20233978 and NCT06569355) across 13 sites in China. Adults aged 18–75…

Read More

Membership is available for $9 per month or $99 per year and includes access to this article, an ad-free website, a customizable member email, access to free tickets and events and more. Most importantly, it provides the support necessary to generate thoughtful, independent journalism. Join today

Read More